

Dated: June 17, 2021
Editorial Office,
World Journal of Hepatology,

Dear Editor,

Thanks a lot for considering our article for review and comments. I am submitting the revised version of our review article entitled "Redefining NAFLD to MAFLD: Is this plausible?" to be considered for publication in the World Journal of Hepatology. Following are the reply to the comments of reviewers and academic editors.

Reviewer #1:

Comment 1: Please, rephrase " NAFLD: A lot has been done, Yet more required ", this type of title is more suited to an informative article than a scientific journal.

Reply Thanks a lot for the valuable suggestion. Content edited

Comment 2: At page 1 Authors wrote [...] Various agents have been used in addition to lifestyle modification, ranging from thioglitazone, vitamin E (antioxidants), metformin to probiotics but none have proven to be useful while adverse effects and long-term safety remained a major concern[...]. However, a recent article (doi:10.3390/nu12113379, PMID: 33153126) suggests that inositol, as Pinitol, reduce liver fat. Please, add these agents and update the reference in this section.

Reply Thanks a lot for the valuable suggestion. Content edited and reference added.

Comment 3: To support the definition of MAFLD in the appropriate paragraph ("The Rise of MAFLD") a recent study analyzed the role of metabolic syndrome and NAFLD on cardiovascular events in patients with atrial fibrillation. The study (doi: 10.1007/s11739-021-02682-3, PMID: 33713286) showed that metabolic syndrome is a major cardiovascular risk factor than NAFLD, which could represent an epiphomenon of the metabolic syndrome itself.

Reply Thanks a lot for the valuable suggestion. Content edited and reference added.

Comment 4: Please, move the text of "Author's two cents" to "Opinion versus evidence"
Reply Thanks a lot for the valuable suggestion. Content edited.

Reviewer #2:

Comment 1: Definition of NAFL in page 1 of <5% should be edited.

Reply Thanks a lot for highlighting the gap. Definition edited.

Comment 2: Page2: thioglitazone should be specify to be Pioglitazone and should remove the metformin and probiotics from this sentence due to the lacking of evidence based to support.

Reply Thanks a lot for your valuable comments. The content was edited and highlighted.

Comment 3: Page3; - correct the small letter to capital letter of FIB-4- in line 5 from bottom

Reply: Correction done.

Comment 4: Page5; - correct and remove the phrase “can we write it” in line 5 from top

Reply: Correction done.

Comment 5: Page5; - correct the small letter to capital letter of NAFLD- in line 8 from bottom

Reply: Correction done.

Comments from Science editor: Issues raised:

Comment 1: PMID and DOI numbers are missing in the reference list. Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references.

Reply: All references are reviewed and edited.

Comment 2: The “Article Highlights” section is missing. Please add the “Article Highlights” section at the end of the main text

Reply: Article highlight section added.

Comments from Company editor-in-chief:

I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Hepatology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office’s comments and the Criteria for Manuscript Revision by Authors. Before final acceptance, the author(s) must add a table/figure to the manuscript.

Reply Thanks a lot for the valuable suggestion. A relevant table and a figure were added.

We hope we will have valuable suggestions from the editorial board & reviewers and hope that this will be interesting for readers and acceptable for publication.

Best regards,
Yours Sincerely

Corresponding Author:
Dr. Amna Subhan Butt
MBBS, FCPS (Medicine), FCPS (Gastroenterology),
MSc Clinical Research, MACG,
Consultant Gastroenterologist,
Section of Gastroenterology
Department of Medicine,
The Aga Khan University,
Stadium Road, Karachi - 74800
Phone: 009221-34864508
Fax: ++92-21-34934294
amna.subhan@aku.edu

Type of manuscript: review article

Title: Redefining Non-alcoholic Fatty Liver Disease to Metabolic Associated Fatty Liver Disease:
Is this plausible?

Running title: Redefining NAFLD to MAFLD: Is this plausible?".

Authors: Amna Subhan Butt, Jalpa Devi, Aimun Raees

1Section of Gastroenterology, Department of Medicine, Aga Khan University Hospital, Karachi